Securian Asset Management Inc. Sells 356 Shares of Hologic, Inc. (NASDAQ:HOLX)

Securian Asset Management Inc. trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 2.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,483 shares of the medical equipment provider’s stock after selling 356 shares during the quarter. Securian Asset Management Inc.’s holdings in Hologic were worth $900,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC raised its holdings in Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares during the period. Sequoia Financial Advisors LLC raised its holdings in Hologic by 14.6% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,468 shares of the medical equipment provider’s stock valued at $610,000 after buying an additional 1,080 shares during the period. AGF Management Ltd. raised its holdings in Hologic by 429.4% during the 4th quarter. AGF Management Ltd. now owns 39,825 shares of the medical equipment provider’s stock valued at $2,871,000 after buying an additional 32,303 shares during the period. Briaud Financial Planning Inc purchased a new stake in Hologic during the 4th quarter valued at $72,000. Finally, Citizens Financial Group Inc. RI purchased a new stake in Hologic during the 4th quarter valued at $249,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Trading Up 0.0 %

Hologic stock opened at $60.71 on Friday. The stock has a 50-day moving average of $67.18 and a two-hundred day moving average of $74.68. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a one year low of $60.33 and a one year high of $84.67. The stock has a market cap of $13.62 billion, a PE ratio of 19.15, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on HOLX. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research note on Monday, February 3rd. Wolfe Research began coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating on the stock. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Morgan Stanley dropped their price target on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, Citigroup dropped their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.